MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
16.50
-0.63
-3.68%
Opening 10:31 06/08 EDT
OPEN
16.95
PREV CLOSE
17.13
HIGH
17.04
LOW
16.47
VOLUME
164.93K
TURNOVER
1.58M
52 WEEK HIGH
25.69
52 WEEK LOW
8.67
MARKET CAP
1.61B
P/E (TTM)
-5.0488
1D
5D
1M
3M
1Y
5Y
Validea Detailed Fundamental Analysis - FGEN
NASDAQ · 1d ago
Notable Wednesday Option Activity: FGEN, SNOW, BLNK
NASDAQ · 1d ago
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 1d ago
Fibrogen Inc: Current report
Press release · 1d ago
FibroGen (FGEN) Receives a Sell from Goldman Sachs
TipRanks · 1d ago
FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal
Benzinga · 1d ago
FGEN Slides after DMD Candidate Fails In Phase 3 Trial
TipRanks · 1d ago
FibroGen Shares Slide After Duchenne Muscular Dystrophy Treatment Falls Short In Trial -- MarketWatch
MarketWatch · 1d ago
More
About FGEN
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of therapeutics. It applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes. It also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Its Roxadustat is approved in China, Europe and Japan for the treatment of anemia in CKD.

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.